Drawing for ZEALAND PHARMA

USPTO serial 79413868

ZEALAND PHARMA

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
VAGHANI, MAYUR C
Law office
TMO LAW OFFICE 124

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with ZEALAND PHARMA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for medical purposes; synthetic peptides for pharmaceuticals purposes; pharmaceutical preparations for the treatment of diseases, illnesses and ailments in humans, such as pharmaceutical preparations for treating endocrine disorders, immunity disorders, nutritional and metabolic diseases, such as diabetes and obesity; pharmaceutical preparations for the treatment and prevention of hypoglycemia; hypoglycemic agents; medical preparations in the nature of a liquid solution for medical purposes for the treatment and prevention of hypoglycemia; pharmaceutical preparations for treating gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; pharmaceutical preparations altering the immune system, such as complement inhibitors; apparatus and instruments containing pharmaceutical preparations, substances and medicines; medical rescue injection pens containing glucagon to treat severe cases of low blood sugar; pre-filled syringes for medical purposes.ACTIVE—
009Computer software, including application software for smartphones [mobile phones], for tablet computers and other handheld or portable personal computers and for personal computers, all for determining treatment recommendations, dose calculation and patient support programs in the nature of providing medical information; databases and software, including application software and databases for use in connection with medical diagnosing, treatment, treatment planning and patient support programs; downloadable software configured for insulin monitoring and tracking blood glucose levels; downloadable software configured for the collection, editing, organizing, modifying, book marking, transmission, storage, sharing and analysis of data and information in the field of diabetes management; wearable devices for insulin monitoring; computer hardware and software for use with medical injection devices for collecting, transmitting and displaying medical data; medical software for the management of diabetes, obesity or gastrointestinal diseases; electronic publications, namely, leaflets, books, booklets, handouts, magazines as well as medical, instructional and teaching material in the field of diabetes, obesity and gastrointestinal diseases.ACTIVE—
010Instruments and apparatus for administering pharmaceuticals; medical devices, namely, diabetes management devices, infusion and injection devices, infusion pumps, infusion pump controllers and parts and attachments thereof; medical devices and sensors used to continuously monitor the concentration of glucose in the human body; glucose monitors; glucose monitor accessories, namely, transmitters, receivers, and medical sensor insertion devices; wearable medical devices for insulin monitoring; infusion pumps for improvement of glycemic control and auto-injector pens for the treatment of hypoglycemia; medical rescue injection pens for administrating glucagon; parts and accessories for all the aforesaid goods.ACTIVE—
042Scientific and technological services and research and design relating thereto in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; industrial analysis and research services in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; medical, biological, biotechnological, genetic, laboratory and pharmaceutical research, design and development services; laboratory research in the field of medicine, pharmaceuticals, genetics, biology and biotechnology; information and consultancy services relating to all the aforesaid; providing scientific information on diabetes, obesity and gastrointestinal diseases; hosting of websites and mobile apps in relation to technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity and gastrointestinal diseases; computer services, namely providing access to data concerning medical analysis and management of diabetes, obesity and gastrointestinal diseases; clinical trials.ACTIVE—
044Medical services; medical analysis services for the diagnosis and treatment of humans; medical consulting services in the field of diseases, illnesses and ailments in humans; medical services related to the testing and treatment of patients with diabetes or low blood sugar (hypoglycemia); medical services related to testing and treatment of patients with gastrointestinal diseases, such as short bowel syndrome and ulcerative colitis; medical consulting services, namely, providing patient adherence programs to patients suffering from diabetes, obesity or gastrointestinal diseases; providing medical information via a website that provide a patient adherence program to patients suffering from diabetes, obesity or gastrointestinal diseases; medical information services, namely, providing information relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical advisory services, namely providing advisory services relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical services in the nature of patient support relating to the treatment of diabetes, obesity or gastrointestinal diseases; medical information and advice in relation to treatment planning, including information and advice provided via the Internet, databases and application software; consultancy services relating to the aforesaid.ACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 29, 2026FINTFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 12, 2026FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 10, 2026FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jun 18, 2026OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jun 1, 2026OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
May 31, 2026OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
Oct 10, 2025MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Oct 10, 2025ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Apr 12, 2025RFNTREFUSAL PROCESSED BY IB—
Mar 27, 2025RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 27, 2025RFRRREFUSAL PROCESSED BY MPU—
Feb 19, 2025RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Feb 19, 2025CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 19, 2025DOCKASSIGNED TO EXAMINER—
Jan 7, 2025MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 7, 2025NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 2, 2025REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance